Your browser doesn't support javascript.
loading
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.
Cheng, Ann-Lii; Qin, Shukui; Ikeda, Masafumi; Galle, Peter R; Ducreux, Michel; Kim, Tae-You; Lim, Ho Yeong; Kudo, Masatoshi; Breder, Valeriy; Merle, Philippe; Kaseb, Ahmed O; Li, Daneng; Verret, Wendy; Ma, Ning; Nicholas, Alan; Wang, Yifan; Li, Lindong; Zhu, Andrew X; Finn, Richard S.
  • Cheng AL; Department of Oncology, National Taiwan University Cancer Center and National Taiwan University Hospital, Taipei, Taiwan. Electronic address: alcheng@ntu.edu.tw.
  • Qin S; Department of Medical Oncology, People's Liberation Army Cancer Center, Nanjing, People's Republic of China.
  • Ikeda M; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Galle PR; Department of Internal Medicine, University Medical Center Mainz, Mainz, Germany.
  • Ducreux M; Department of Medical Oncology, Gustave Roussy Cancer Center, Villejuif, France.
  • Kim TY; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea.
  • Lim HY; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Kudo M; Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
  • Breder V; Department of Chemotherapy, N. N. Blokhin Russian Cancer Research Center, Moscow, Russia.
  • Merle P; Department of Gastroenterology and Hepatology, University Hospital La Croix-Rousse, Lyon, France.
  • Kaseb AO; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Li D; Department of Medical Oncology, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA, USA.
  • Verret W; Product Development Oncology, Genentech, Inc., South San Francisco, CA, USA.
  • Ma N; Product Development Safety, Genentech, Inc., South San Francisco, CA, USA.
  • Nicholas A; Product Development Biostatistics, Genentech, Inc., South San Francisco, CA, USA.
  • Wang Y; Product Development Biostatistics, Roche Product Development, Shanghai, People's Republic of China.
  • Li L; Product Development Medical Affairs, Roche Product Development, Shanghai, People's Republic of China.
  • Zhu AX; Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, MA, USA; Jiahui International Cancer Center, Jiahui Health, Shanghai, People's Republic of China.
  • Finn RS; Department of Medicine, Division of Hematology and Oncology, Jonsson Comprehensive Cancer Center, Geffen School of Medicine at UCLA, Los Angeles, CA, USA. Electronic address: RFinn@mednet.ucla.edu.
J Hepatol ; 76(4): 862-873, 2022 Apr.
Article en En | MEDLINE | ID: mdl-34902530
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article